AndreMichel Ballester - LivaNova PLC CEO, Executive Director

LIVN Stock  USD 55.94  0.92  1.67%   

CEO

Mr. AndreMichel Ballester is no longer Chief Executive Officer Executive Director of the Company effective on December 31 2016. Since 14 September 2015. AndrMichel Ballester is the current chief executive officer of Sorin and was appointed to this role in September 2007. From 2004 to September 2007 he was president of Sorins Cardiac Rhythm Management Business Unit. AndrMichel was from 2000 to 2004 Corporationrationrate Vice President EMEA Asia and Latin America for Edwards Lifesciences. AndrMichel spent his professional background in Edwards Lifesciences and Baxter where he participated in the successful spinoff of Edwards Lifesciences from Baxter. For over 10 years prior to Edwards spinoff AndrMichel held several executive positions in Baxter in Europe and in the USA and was appointed president of the CardioVascular Group Europe in 1997. Currently AndrMichel also serves as Independent Director of the Board of Carmat SA and of Mauna Kea Technologies listed medtech French companies. In 2012 AndrMichel was appointed as a Chevalier dans lordre de la Lgion dHonneur in France. Born in Orleansville Algeria and raised in France AndrMichel received his M.S. degree in Engineering from Ecole Centrale Lille France and his M.B.A. from INSEAD Fontainebleau France. since 2015.
Age 47
Tenure 9 years
Professional MarksMBA
Address 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
Phone44 20 3325 0660
Webhttps://www.livanova.com

LivaNova PLC Management Efficiency

The company has return on total asset (ROA) of 0.0176 % which means that it generated a profit of $0.0176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0141 %, meaning that it created $0.0141 on every $100 dollars invested by stockholders. LivaNova PLC's management efficiency ratios could be used to measure how well LivaNova PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.01. Also, Return On Capital Employed is likely to grow to 0.05. At this time, LivaNova PLC's Intangible Assets are very stable compared to the past year. As of the 24th of April 2024, Net Tangible Assets is likely to grow to about 116.1 M, while Deferred Long Term Asset Charges is likely to drop about 4.8 M.
The company currently holds 640.4 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. LivaNova PLC has a current ratio of 2.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist LivaNova PLC until it has trouble settling it off, either with new capital or with free cash flow. So, LivaNova PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like LivaNova PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for LivaNova to invest in growth at high rates of return. When we think about LivaNova PLC's use of debt, we should always consider it together with cash and equity.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. Livanova Plc operates under Medical Equipment classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. LivaNova PLC (LIVN) is traded on NASDAQ Exchange in USA. It is located in 20 Eastbourne Terrace, London, United Kingdom, W2 6LG and employs 2,900 people. LivaNova PLC is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

LivaNova PLC Leadership Team

Elected by the shareholders, the LivaNova PLC's board of directors comprises two types of representatives: LivaNova PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LivaNova. The board's role is to monitor LivaNova PLC's management team and ensure that shareholders' interests are well served. LivaNova PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LivaNova PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pritpal Shinmar, Senior Vice President - Global Market Access
Daniel Moore, Non-Executive Chairman of the Board
Stephanie Bolton, President Epilepsy
Alfred Novak, Independent Director
Arthur Rosenthal, Independent Director
Matthew III, Senior IT
Jacques Gutedel, President - Intercontinental
Deanna Wilke, Vice Communications
John Webb, Vice Epilepsy
Keyna Skeffington, Senior Vice President General Counsel
Francesco Bianchi, Independent Director
Demetrio Mauro, Chief Integration Officer
Sharon OKane, Independent Director
Vivid Sehgal, CFO
Hugh Morrison, Independent Director
Marco Dolci, Pres Unit
Lindsey Little, Director Relations
Damien McDonald, CEO Director
William Kozy, Chairman CEO
Brian Sheridan, Senior Vice President General Counsel, Company Secretary
David Wise, Chief Admin. Officer, Sr. VP and Secretary
AndreMichel Ballester, CEO, Executive Director
Andrea Saia, Non-Executive Independent Director
Badri Amurthur, Chief Officer
Michel Darnaud, President - Cardiac Surgery
Piero Vecchi, Vice President Controller
Trui Hebbelinck, Chief Human Resource Officer
Rohan Hoare, COO
Edward Andrle, Senior Vice President - Strategy & Business Development
Michael Hutchinson, Chief VP
Douglas Manko, Chief Accounting Officer
Ryan Miller, President Support
Stefano Gianotti, Independent Director
Thad Huston, CFO
Alex Shvartsburg, Chief Officer
Karen King, Vice President - Investor Relations and Corporate Communications
Bryan Olin, Senior Neuromodulation
Vladimir Makatsaria, CEO Director
Stefano Lullo, President - Cardiac Rhythm Management
Jonathan Walker, VP Segment

LivaNova Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LivaNova PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether LivaNova PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of LivaNova PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Livanova Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Livanova Plc Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LivaNova PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
To learn how to invest in LivaNova Stock, please use our How to Invest in LivaNova PLC guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for LivaNova Stock analysis

When running LivaNova PLC's price analysis, check to measure LivaNova PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LivaNova PLC is operating at the current time. Most of LivaNova PLC's value examination focuses on studying past and present price action to predict the probability of LivaNova PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LivaNova PLC's price. Additionally, you may evaluate how the addition of LivaNova PLC to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
CEOs Directory
Screen CEOs from public companies around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is LivaNova PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LivaNova PLC. If investors know LivaNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LivaNova PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
9.026
Earnings Share
0.32
Revenue Per Share
21.386
Quarterly Revenue Growth
0.128
Return On Assets
0.0176
The market value of LivaNova PLC is measured differently than its book value, which is the value of LivaNova that is recorded on the company's balance sheet. Investors also form their own opinion of LivaNova PLC's value that differs from its market value or its book value, called intrinsic value, which is LivaNova PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LivaNova PLC's market value can be influenced by many factors that don't directly affect LivaNova PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LivaNova PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if LivaNova PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LivaNova PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.